Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Peter Kraft

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4472-8103; OpenAlex author ID A5056487867; NIH RePORTER profile ID 8393783. Sources: OpenAlex.

Their work

Papers
48 (first author 1, last author 3)
Trials
0
Grants
1
Labs led
1
Collaborators
76
Papers, trials and grants by year

2012: 3 papers · 2013: 7 papers · 2014: 3 papers · 2015: 2 papers · 2016: 3 papers, 1 grant · 2017: 2 papers · 2018: 3 papers · 2019: 3 papers · 2020: 5 papers · 2021: 4 papers · 2022: 1 paper · 2023: 6 papers · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 48

  1. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  2. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  3. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  4. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  5. Transcriptome-wide association study and Mendelian randomization in pancreatic cancer identifies susceptibility genes and causal relationships with type 2 diab… Co-author DOI 10.1016/j.ebiom.2024.105233↗
  6. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-24-0096↗
  7. Pancreatic cancer is associated with medication changes prior to clinical diagnosis. Co-author DOI 10.1038/s41467-023-38088-2↗
  8. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. Co-author DOI 10.1038/s41591-023-02332-5↗
  9. Relationship between ABO Blood Group Alleles and Pancreatic Cancer Is Modulated by Secretor (FUT2) Genotype, but Not Lewis Antigen (FUT3) Genotype. Last author DOI 10.1158/1055-9965.epi-23-0009↗
  10. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  11. Sex-Specific Associations between Adiponectin and Leptin Signaling and Pancreatic Cancer Survival. Co-author DOI 10.1158/1055-9965.epi-23-0505↗
  12. Helicobacter pylori Seropositivity, ABO Blood Type, and Pancreatic Cancer Risk From 5 Prospective Cohorts. Co-author DOI 10.14309/ctg.0000000000000573↗
  13. The age-dependent association of risk factors with pancreatic cancer. Co-author DOI 10.1016/j.annonc.2022.03.276↗
  14. A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Co-author DOI 10.1016/j.ajhg.2021.09.002↗
  15. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Co-author DOI 10.1093/ajcn/nqab217↗
  16. Prediagnostic Inflammation and Pancreatic Cancer Survival. Co-author DOI 10.1093/jnci/djab040↗
  17. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  18. Diabetes, Weight Change, and Pancreatic Cancer Risk. Co-author DOI 10.1001/jamaoncol.2020.2948↗
  19. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  20. Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. Last author DOI 10.1158/1055-9965.epi-19-1389↗
  21. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  22. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗
  23. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Co-author DOI 10.1038/s41416-019-0426-5↗
  24. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  25. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Co-author DOI 10.1158/1055-9965.epi-19-0577↗
  26. Statin use and pancreatic cancer risk in two prospective cohort studies. Co-author DOI 10.1007/s00535-018-1430-x↗
  27. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2018.02.022↗
  28. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studie… Co-author DOI 10.1053/j.gastro.2017.12.001↗
  29. Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-312510↗
  30. Cigarette Smoking and Pancreatic Cancer Survival. Co-author DOI 10.1200/jco.2016.71.2026↗
  31. Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. Co-author DOI 10.1093/jnci/djv409↗
  32. Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Co-author DOI 10.1158/0008-5472.can-16-1699↗
  33. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. Co-author DOI 10.1200/jco.2015.66.3005↗
  34. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  35. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. Co-author DOI 10.1200/jco.2014.57.5688↗
  36. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  37. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Co-author DOI 10.1038/nm.3686↗
  38. Genome-wide association study of survival in patients with pancreatic adenocarcinoma. First author DOI 10.1136/gutjnl-2012-303477↗
  39. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Co-author DOI 10.1007/s10552-012-0078-8↗
  40. Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4. Co-author DOI 10.1007/s10552-012-0138-0↗
  41. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. Co-author DOI 10.1093/jnci/djs474↗
  42. Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. Co-author DOI 10.1093/jnci/djt123↗
  43. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts. Co-author DOI 10.1158/1055-9965.epi-12-1458↗
  44. Prediagnostic body mass index and pancreatic cancer survival. Co-author DOI 10.1200/jco.2013.51.7532↗
  45. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. Last author DOI 10.1371/journal.pone.0072311↗
  46. Unidentified genetic variants influence pancreatic cancer risk: an analysis of polygenic susceptibility in the PanScan study. Co-author DOI 10.1002/gepi.21644↗
  47. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Co-author DOI 10.1093/carcin/bgs151↗
  48. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Co-author DOI 10.1158/1055-9965.epi-11-0836↗

Grants 1

  1. Leveraging GxE interaction to understand pancreatic cancer and altered metabolism UH2CA191284↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 27 shared papers, 2012–2023 · strength 1.96
  2. Chen Yuan · 22 shared papers, 2013–2023 · strength 1.83
  3. Edward L. Giovannucci · 25 shared papers, 2012–2023 · strength 1.62
  4. Kimmie Ng · 20 shared papers, 2012–2023 · strength 1.49
  5. Ana Babić · 16 shared papers, 2016–2023 · strength 1.35
  6. Charles S. Fuchs · 22 shared papers, 2012–2023 · strength 1.34
  7. JoAnn E. Manson · 16 shared papers, 2012–2023 · strength 0.97
  8. Jihye Kim · 5 shared papers, 2020–2023 · strength 0.70
  9. Jonathan Andrew Nowak · 7 shared papers, 2018–2023 · strength 0.67
  10. Vicente Morales‐Oyarvide · 10 shared papers, 2016–2021 · strength 0.65
  11. Laufey Thora Amundadottir · 8 shared papers, 2013–2023 · strength 0.62
  12. Kimberly J. Perez · 5 shared papers, 2019–2023 · strength 0.57
  13. Natalia I. Khalaf · 7 shared papers, 2018–2021 · strength 0.55
  14. Douglas Adam Rubinson · 10 shared papers, 2013–2020 · strength 0.55
  15. Alice A. Lee · 4 shared papers, 2022–2023 · strength 0.53
  16. Qiao-Li Wang · 4 shared papers, 2022–2023 · strength 0.53
  17. Zhi Rong Qian · 12 shared papers, 2013–2018 · strength 0.53
  18. Ying Bao · 10 shared papers, 2012–2020 · strength 0.41
  19. Alison P. Klein · 3 shared papers, 2020–2023 · strength 0.39
  20. Michael Hayden Rosenthal · 3 shared papers, 2020–2023 · strength 0.38
  21. Chris Sander · 3 shared papers, 2020–2023 · strength 0.38
  22. Tsuyoshi Hamada · 5 shared papers, 2018–2019 · strength 0.35
  23. Jean Wactawski‐Wende · 4 shared papers, 2012–2023 · strength 0.33
  24. Harvey A. Risch · 2 shared papers, 2022–2023 · strength 0.30
  25. Rachael Z. Stolzenberg‐Solomon · 4 shared papers, 2013–2022 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.